Search Results
Your search for all items matches 34700 pages
Showing 12151 - 12200Study Finds Alpelisib Effective After CDK4/6 Inhibition in Advanced Breast Cancer
The PIK3CA inhibitor alpelisib appears to be effective in patients with PIK3CA-positive, hormone receptor–positive/HER2-negative advanced breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor plus an aromatase inhibitor, according to the phase II BYLieve trial.1 More...
Survey Shows Young-Onset Colorectal Cancer May Be Overlooked in Exam Rooms
The Colorectal Cancer Alliance recently released findings from its latest survey of patients with young-onset colorectal cancer and survivors. The Never Too Young Survey shares the self-reported medical, psychosocial, and quality-of-life experiences of this often-overlooked population to better...
ASCO20 Virtual Scientific Program: Next-Generation Oncology Highlights
The ASCO20 Virtual Scientific Program was different in many ways, not only because of the virtual modality forced by the COVID-19 pandemic, but also because of the resilience of the scientific society and my colleagues around the world. I’m in the plenary session of the ASCO 2025 Annual Meeting....
American Association for Cancer Research Announces Distinguished Public Service Award Recipients
The American Association for Cancer Research (AACR) recently announced the presentation of Distinguished Public Service Awards to four individuals whose work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, ...
MSK–Hackensack Meridian Health Partnership Collaborate on Immunology Research Projects
Memorial Sloan Kettering Cancer Center (MSK) and Hackensack Meridian Health recently announced they have formed an Immunology Research Collaboration. Through this joint initiative, researchers can apply for funding to support innovative investigations exploring the power of the immune system and...
Jackson Laboratory Cancer Center Receives Continued Recognition, Funding by NCI
The Jackson Laboratory (JAX), a basic science research center with locations throughout the state of Maine, recently announced the National Cancer Center has renewed its Cancer Center Support Grant for the 34th year. The Jackson Laboratory is one of seven basic research centers with this...
Fox Chase–Temple University Hospital Announces Bone Marrow Transplant Program
The Fox Chase–Temple University Hospital Bone Marrow Transplant (BMT) Program recently announced it will introduce a Department of Bone Marrow Transplant and Cellular Therapies on July 1, 2020. Henry Chi Hang Fung, MD, FACP, FRCPE, Current Director of the Bone Marrow Transplant Program and Vice...
Cancer Researcher Grzegorz Ira, PhD, Honored With Baylor’s DeBakey Award
Select Baylor College of Medicine faculty are honored annually through the Michael E. DeBakey, MD, Award for Excellence in Research for outstanding published scientific contributions to clinical and basic science research over a 3-year period. Included among the honorees for this year’s DeBakey...
Brigatinib for ALK-Positive Metastatic Non–Small Cell Lung Cancer
On May 22, 2020, brigatinib was approved for the treatment of adult patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion...
AACR Inaugurates New Leadership
The American Association for Cancer Research (AACR) welcomes Antoni Ribas, MD, PhD, FAACR, as President of the organization for 2020–2021. He was inaugurated during the AACR Annual Business Meeting, held virtually on April 29, 2020. Dr. Ribas is Professor of Medicine at the David Geffen School of...
Determining the Best Place to Die for Patients With Cancer
Studies have shown a disconnect between where patients say they want to die and where they actually die. According to research from Stanford School of Medicine, although an overwhelming majority of Americans—about 80%—would prefer to die at home, just 20% do. In fact, 60% die in acute care...
Ganesh Rao, MD, Named Chair of Neurosurgery at Baylor College of Medicine
Baylor College of Medicine recently announced that Ganesh Rao, MD, has been named the new Chair of the Department of Neurosurgery. In this role, he also will hold the Marc J. Shapiro Endowed Chair at Baylor and will serve as the Neurosurgery Service Line Chief across the Catholic Health...
Blood Test Improves Screening for Hepatocellular Carcinoma
Researchers at the National Institutes of Health have developed a new test that may help identify individuals who may be likely to develop hepatocellular carcinoma. A study of the new approach was led by researchers at the National Cancer Institute (NCI). The findings were published in the journal...
Global Study Indicates Oncology Pharmacists Face Restricted Access to Essential PPE
Oncology pharmacy practitioners around the world are fighting to provide patients who have cancer with high-quality care despite increasingly limited and sometimes restricted personal protective equipment (PPE) as well as impaired access to essential anticancer medication, according to study...
ASCO Survey on Early Impact of COVID-19 on Performance of Oncology Clinical Trials
In an article published in JCO Oncology Practice, David Waterhouse, MD, MPH, of Oncology Hematology Care, Cincinnati, Ohio, and colleagues presented the results of a recent ASCO survey of clinical programs on the early impact of the COVID-19 pandemic on the performance of oncology clinical...
Ruxolitinib Improves Response Rates in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Allogeneic SCT
In the phase III REACH2 trial reported in TheNew England Journal of Medicine, Robert Zeiser, MD, of the Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Center Freiburg, Germany, and colleagues found that the JAK1/2 inhibitor ruxolitinib improved response rate...
Acalabrutinib With or Without Obinutuzumab vs Chlorambucil/Obinutuzumab in Previously Untreated CLL
As reported inThe Lancet by Jeff P. Sharman, MD, of Willamette Valley Cancer Institute/US Oncology, Eugene, Oregon, and colleagues, the phase III ELEVATE-TN trial has shown significantly improved progression-free survival with both acalabrutinib/obinutuzumab and acalabrutinib monotherapy vs...
Ramucirumab Plus Erlotinib in Treatment of EGFR-Mutant Metastatic NSCLC
On May 29, 2020, ramucirumab was approved for use in combination with erlotinib for first-line treatment of metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation.1,2 Supporting Efficacy Data Approval was based on findings from the...
First-Line Atezolizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs...
Improving Care for Women With Late-Stage Breast Cancer
The global toll of breast cancer on women is staggering. In 2018, nearly two million new breast cancer cases were diagnosed, an increase of more than 20% since 2008,1 and mortality rates have increased by 14%, bringing the annual number of deaths worldwide from the cancer to more than 611,625.2...
Olaparib for Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 19, 2020, olaparib was approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer who experienced disease progression after treatment with...
Ripretinib in Previously Treated Advanced Gastrointestinal Stromal Tumor
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 15, 2020, the receptor tyrosine kinase inhibitor...
Expert Point of View: Suzette Delaloge, MD, MSc
Commenting on the final overall survival analysis of the LOTUS trial, the study’s invited discussant, Suzette Delaloge, MD, MSc, Chair of the Breast Cancer Group at the Institut Gustave Roussy, Paris, said: “We see there might also be an overall survival effect with ipatasertib and paclitaxel…....
Benefit Shown for AKT Inhibitor in LOTUS Survival Analysis
In the phase II LOTUS trial, the addition of the AKT inhibitor ipatasertib to paclitaxel in the first-line treatment of patients with advanced triple-negative breast cancer yielded a strong numerical improvement—a median gain of 9 months—in overall survival, in the final survival analysis reported...
Expert Point of View: Antonio Llombart-Cussac, MD, PhD
Discussant of the abstracts, Antonio Llombart-Cussac, MD, PhD, of Hospital Arnau de Vilanova, Universidad Catolica Valencia, Spain, noted that establishing these regimens in the third-line setting of metastatic disease and beyond will require demonstration of consistent gains in both...
Newer Late-Line Treatments May Change Front-Line Standard of Care in HER2-Positive Metastatic Breast Cancer
First- and second-line treatments of HER2-positive metastatic breast cancer have become the standard of care based on solid gains in overall survival, but the prevalence of resistance to these agents is increasing; up to 55% of patients will ultimately develop brain metastases. According to a pair...
Northwell Health Cancer Institute of New York Appoints Oncology Experts to Lead New Programs
The Northwell Health Cancer Institute of Northwell Health in New Hyde Park, New York, has recruited four experts to strengthen its cancer care management, survivorship programs, oncology nursing, cancer research, and oncology surgery at locations throughout Long Island and Westchester county:...
ASCO20 Virtual Scientific Program Convened Record Number of Oncology Professionals From Across the Globe
ASCO announced record-breaking attendance at its 3-day ASCO20 Virtual Scientific Program, held online from May 29 through May 31. More than 42,700 attendees from 138 countries have participated thus far, learning virtually about new clinical cancer advances in every area of cancer research....
Repeat Breast Preservation: First Consideration in a Second Ipsilateral Breast Tumor Event
Worldwide, nearly 1.7 million women will be diagnosed with breast cancer. Of that number, nearly 300,000 Americans and more than 500,000 Europeans will be diagnosed with both invasive and in situ breast cancers.1,2 Breast-preserving surgery will initially be performed on approximately 60% of...
Responding to Racism and Health Inequality as a Cancer Care Community
Months ago, when I defined a theme for my year as ASCO President, “Equity: Every Patient. Every Day. Everywhere,” I never imagined we would experience a health-care pandemic that would disproportionally impact people of color. Nor could I know this would be the moment when yet another brutal crime ...
Expert Point of View: Taofeek Kunie Owonikoko, MD, PhD
Study discussant Taofeek Kunie Owonikoko, MD, PhD, Professor and Vice Chair of Hematology/Oncology, Winship Cancer Institute at Emory University, Atlanta, had praise for the design of KEYNOTE-604. He noted the adoption of the combination of pembrolizumab plus etoposide/platinum for the treatment of ...
First-Line Pembrolizumab Added to Standard Chemotherapy Improved Progression-Free Survival in Extensive-Stage Small Cell Lung Cancer
Pembrolizumab added to etoposide and platinum significantly improved progression-free survival compared with placebo and etoposide/platinum as first-line therapy in patients with newly diagnosed, extensive-stage small cell lung cancer (SCLC).1 These results from the randomized, double-blind, phase...
FDA Approves Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
On June 24, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable with surgery or radiation. KEYNOTE-629 Efficacy was investigated in KEYNOTE-629, a multicenter, multicohort,...
International Consortium Aims to Enhance Decision-Making in Hodgkin Lymphoma
Harmonization of big data in examining acute and long-term outcomes with contemporary treatment for pediatric and adult patients with Hodgkin lymphoma is yielding a new approach to inform future clinical trial design and enhance clinical decision-making, according to a statement by Rutgers Cancer...
Highlights From Complementary and Integrative Medicine Research and Implications for Clinical Practice
Due to COVID-19, this year’s ASCO Annual Meeting was convened using a virtual format. It was multidisciplinary, featuring more than 250 oral and 2,500 poster presentations from around the world in 24 disease-based and specialty tracks. Among the exciting talks in the session on symptoms and...
Underrepresentation of Black Patients in Cancer Clinical Trials: Public vs Pharmaceutical Sponsorship
Black patients are better represented in taxpayer-funded cancer clinical trials compared to trials run by pharmaceutical companies, although they remain underrepresented in clinical trials, regardless of sponsor. These results were published by Joseph M. Unger, PhD, and colleagues in JNCI Cancer...
FDA Announces Project Patient Voice to Communicate Patient-Reported Outcomes From Cancer Clinical Trials
The U.S. Food and Drug Administration (FDA) has launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer ...
Results of a COVID-19 and Cancer Consortium (CCC19) Cohort Study
As reported in The Lancet by Kuderer et al, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of severe COVID-19 in patients with cancer is associated with such factors as age, comorbidities, performance status, hematologic malignancy, and...
Efficacy Outcomes With C-MTX in Newly Diagnosed Patients With Pediatric T-Cell Lymphoblastic Lymphoma
As reported in the Journal of Clinical Oncology by Hayashi et al, the Children’s Oncology Group AALL0434 study has shown “excellent” outcomes with Capizzi-based methotrexate/pegaspargase (C-MTX) treatment in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL). The addition...
Paul G. Richardson, MD, on Multiple Myeloma: First-in-Human Study of the Novel Agent CC-92480
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses early results on a cereblon E3 ligase modulator agent combined with dexamethasone in patients with relapsed or refractory multiple myeloma, with an overall response rate of 48%. The study is ongoing to further optimize dose and...
Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment
Patricia Pautier, MD, of Institut Gustave Roussy, discusses final results of the phase II LMS-02 study, which showed the combination of doxorubicin and trabectedin to be an effective first-line therapy for patients with leiomyosarcoma, with an acceptable safety profile (Abstract 11506).
Nikhil C. Munshi, MD, on Multiple Myeloma: Idecabtagene Vicleucel in Patients With Relapsed or Refractory Disease
Nikhil C. Munshi, MD, of Dana-Farber Cancer Institute, discusses initial results from the KarMMa tria, showing that idecabtagene vicleucel, a B-cell maturation antigen-targeted CAR T-cell therapy, demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory...
Expert Point of View: Michael S. Lee, MD, and Autumn McRee, MD
DESTINY-CRC01 study discussant, Michael S. Lee, MD, Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, called the findings “most promising” for the subsequent anti-HER2 treatment of HER2-positive metastatic colorectal cancer. The...
Trastuzumab Deruxtecan Shows Benefit in Refractory Colorectal Cancer
Having recently gained approval in metastatic breast cancer, fam-trastuzumab deruxtecan-nxki (T-DXd) is now proving its worth in metastatic colorectal cancer, according to results of the phase II DESTINY-CRC01 study in patients with HER2-positive disease.1 T-DXd is an antibody-drug conjugate...
Study Links Financial Hardship to More Emergency Room Visits, Less Preventive Care Among Cancer Survivors
A new study has found higher medical and nonmedical financial hardships are independently associated with more emergency department visits, lower receipt of some preventive services, and worse self-rated health in cancer survivors. The authors of the study warn that as health-care costs grow, unmet ...
Prognosis of Patients With Stage III Melanoma According to AJCCv8 vs Independent Cohorts
In a study reported in the Journal of Clinical Oncology, Garbe et al found that melanoma-specific survival rates for patients with stage III disease differed markedly in three independent cohorts compared with those reported in American Joint Committee on Cancer version 8 (AJCCv8) stage III...
Lipophilic Statins May Reduce Mortality in Patients With Ovarian Cancer
Lipophilic statins—a type of medication commonly prescribed to lower blood cholesterol—were associated with reduced mortality in patients with ovarian cancer, according to a study presented by Kala Visvanathan, MD, MHS, and colleagues at the American Association for Cancer Research (AACR) Virtual...
Ivosidenib for IDH1-Mutant Advanced Glioma
In a phase I study reported in the Journal of Clinical Oncology, Mellinghoff et al found that ivosidenib was well tolerated in patients with IDH1-mutant advanced glioma and was associated with prolonged disease control in those with nonenhancing glioma. Study Details The study included 66 evaluable ...
ASTRO Issues Clinical Guideline on Radiation Therapy for Cervical Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline—ASTRO's first for cervical cancer—outlines indications and best practices for external-beam radiation...
FDA Approves Selinexor for Relapsed or Refractory DLBCL
On June 22, the U.S. Food and Drug Administration (FDA) approved oral selinexor (Xpovio), a first-in-class, selective inhibitor of nuclear export compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified after at least...
